Medicaid Drug Utilization Review Board
Meeting Agenda for February 16, 2017

The Drug Utilization Review (DUR) Board will meet on February 16, 2017 from 9:00 a.m. to 4:00 p.m. Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

Agenda Items

A. Drug Utilization Reviews
   1. Atypical Antipsychotic Medication Duplicative Therapy
   2. Medication Management of Persistent Asthma
   3. Hepatitis-C Direct Acting Antiviral Clinical Updates and Drug Interactions
   4. Anti-Retroviral Drug Interaction Updates
   5. Zolpidem Clinical Updates

B. Clinical Editing Reviews
   1. Inhaled Corticosteroids
   2. Long Acting Beta-Agonists (LABA)
   3. Inhaled Corticosteroid/LABA Combinations
   4. Intranasal Corticosteroids
   5. Montelukast
   6. Ophthalmic Fluoroquinolones
   7. Oral Pollen/Allergen Extracts
   8. Proton Pump Inhibitors

C. Programmatic Updates
   1. Gabapentin - Educational Letter
   2. Prescriber Education Program
**Agenda Timeline** (subject to change based on meeting proceedings)

<table>
<thead>
<tr>
<th>Time</th>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:15</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td>9:15 - 10:15</td>
<td>Public Comment Period*</td>
</tr>
<tr>
<td>10:15 - 12:30</td>
<td>Agenda Items (from list above)</td>
</tr>
<tr>
<td>12:30 - 1:30</td>
<td>Lunch/Executive Session</td>
</tr>
<tr>
<td>1:30 - 3:45</td>
<td>Agenda Items (from list above)</td>
</tr>
<tr>
<td>3:45 - 4:00</td>
<td>Final Comments and Adjournment</td>
</tr>
</tbody>
</table>

* Interested parties must notify the Department of Health (the Department) by February 8, 2017 of their request to address the DUR Board during the public comment period. Requests may be made by phone (518-486-3209) or e-mail (dur@health.ny.gov). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes.

All written statements must be received by the Department in an electronic format (dur@health.ny.gov) no later than one (1) week prior to the meeting. Written statements should summarize key points and may not exceed two (2) pages in length. If the submission of clinical information greater than two (2) pages in length is needed, the information must be received at least two (2) weeks prior to the meeting or the Board may not have ample time to review such information. Please contact Department staff by e-mail (dur@health.ny.gov) prior to sending any information greater than two (2) pages.

Note: All information must be submitted to the Department. Information should not be submitted directly to DUR Board members. The Department will ensure that all information received (according to the guidelines above) is available for DUR Board member review prior to the meeting.